Hops
Also sold as: Hops · Humulus lupulus · Hop cones
A botanical used in calming products and valerian combinations for sleep. Prenylflavonoids, including estrogenically active 8-prenylnaringenin, make formulation and safety context important.
Sleep Anxiety
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Sleep: Small sleep trials mainly tested valerian+hops combinations; the separate contribution of hops is not established.
- Anxiety: One small four-week crossover pilot improved self-reported anxiety/stress in apparently healthy young adults, not diagnosed clinical disorders.
REALITY CHECK // Valerian+hops RCTs are regularly marketed as if they proved hops alone is a sleeping pill; they cannot separate its contribution. A small healthy-volunteer mood pilot and preliminary menopause findings do not establish clinical disorder treatment, and natural origin does not cancel estrogenic activity.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Dose range not extracted
The source identifies trial formulations but not a reliable extract-mass interval or marker percentage. Numeric trial comparison is unavailable.
02 // TIMING_&_MATRIX
Tea is not a fixed extract
Hop cones, beverages and standardized extracts have different and variable constituent exposure; no equivalence can be calculated here.
03 // EVALUATION_WINDOW
Four weeks in the mood pilot
Sleep trials ran several weeks; independent replication and long-term safety remain limited.
04 // SAFETY_&_QUALITY_GATE
Sedation and 8-PN gate
Review sedative medicines, driving and estrogen-sensitive conditions. No numeric UL has been established.
UPPER LIMIT // No EFSA/NIH upper intake level is established for hops in this dossier. The absence of a numeric UL does not demonstrate safety of high exposures or long-term use.
Summary
Sleep evidence largely concerns fixed valerian+hops products, with inconsistent superiority over placebo on objective measures. A small mood pilot is insufficient to establish anxiety or depression treatment. Small menopause trials provide a preliminary signal, but estrogenic activity also defines a safety concern.
Mechanism
Humulone, xanthohumol and related constituents modulate GABA-A responses in cell/animal experiments. 8-prenylnaringenin acts at estrogen receptors; preclinical potency cannot quantify human benefit or medicine interactions.
Typical studied dose
The extracted dossier identifies multiweek valerian+hops sleep studies and a four-week hops-extract mood pilot, but does not supply usable human extract dose ranges or marker percentages. Calculator trial thresholds are therefore unavailable rather than invented.
Upper limit
No EFSA/NIH upper intake level is established for hops in this dossier. The absence of a numeric UL does not demonstrate safety of high exposures or long-term use.
Popular stacks with Hops
Not enough stack data yet. A combination with Hops appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Hop cones / hop tea Best for: Recognizing traditional variable-exposure preparations. |
Unstandardized: active content unknown | no comparable trial range | Constituent content varies with cultivar/storage; volatile and oxidation-sensitive compounds complicate standardization. Generally tolerated; bitterness can limit palatability. |
Caution [SOURCE // CHECK_LABEL] No extracted clinical dose threshold or universal active percentage; traditional use is not a standardized trial. |
| Dry hops extract (marker specification required) Best for: Comparing a documented extract specification. |
Unstandardized: active content unknown | no comparable trial range | Oral prenylflavonoid pharmacokinetics have been studied in women using specified extracts. Tolerated in small studies; safety depends on constituent exposure. |
Caution [SOURCE // CHECK_LABEL] The dossier does not give an extract-mass range or actual xanthohumol/8-PN percentage. Do not treat an unspecified marker content as 100%. |
| Fixed valerian+hops extract (Ze 91019 type) Best for: Understanding the formulation underlying most sleep evidence. |
Unstandardized: active content unknown | no comparable trial range | Studied as a whole product; separate hops bioavailability/effect cannot be assigned. Generally tolerated in sleep RCTs, with possible sedation. |
Studied standard [SOURCE // FORM_SPECIFIC] The combination has trial evidence, but the extracted dose/proportion is insufficient for numeric comparison. Do not attribute the entire effect to hops. |
| Nonalcoholic beer / hop-containing beverage Best for: Recognizing an uncontrolled botanical delivery route. |
Unstandardized: active content unknown | no comparable trial range | Exposure is beverage-specific and cannot be equated with a measured extract. Usually tolerated; product matrix varies. |
Caution [SOURCE // CHECK_LABEL] No reliable supplement dose or universal bitter-acid exposure follows from beverage volume. |
Common label traps
- TRAP_01 // HOPS ALONE IS A PROVEN SLEEP MEDICINE
Most human sleep RCTs tested valerian+hops. Small trials and variable placebo superiority leave the independent hops contribution unresolved. - TRAP_02 // NATURAL MEANS NO HORMONAL ACTIVITY
8-PN is estrogenically active in preclinical work; estrogen-sensitive conditions and hormone medicines need review. - TRAP_03 // BITTER HOPS GUARANTEES FAT LOSS
The circulated 3.8%/24-week marketing figure was not verified in the source dossier and is not presented as a clinical result here.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- COMBINATION SLEEP DATA Limited · benefit
Small/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
PMID 16335333 PMID 17486686 PMID 40462685 PMID 17704989 PMID 20628685 - MOOD PILOT Limited · benefit
One double-blind crossover pilot in apparently healthy young adults found lower DASS-21 anxiety/depression/stress scores after four weeks; it is not replicated evidence for clinical anxiety/depression.
PMID 28742505 - MENOPAUSAL SYMPTOMS Limited · benefit
Small standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
PMID 16321485 PMID 23512496 PMID 24314619 PMID 27617238 PMID 17088409 PMID 16076101 - ESTROGENIC PHARMACOLOGY Anecdotal · benefit
8-PN shows estrogen-receptor activity and mammary effects in cell/animal models. This is a safety-relevant pharmacological signal, not a beneficial wellness endpoint or proof of a human cancer outcome.
PMID 11134162 PMID 32945668 PMID 28964928 PMID 23874474 - WEIGHT-LOSS CLAIM No established evidence
The source did not verify the circulating bitter-hop nutraceutical weight-loss finding in peer-reviewed human literature; no efficacy conclusion or numeric effect is assigned.
Reader questions
Is hops alone as well supported as valerian+hops?
No. Most sleep evidence belongs to fixed combinations, which cannot isolate the hops contribution.
Is hop tea equivalent to an extract?
No reliable equivalence is available; cultivar, storage, extraction and marker specification vary.
Can I use hops with hormone treatment or before driving?
Sedation can impair driving. Hormone-sensitive conditions or hormone medicines need individualized review because of estrogenic constituents and sparse interaction data.
Stack interactions
- Caution Alcohol, benzodiazepines, hypnotics and sedating antihistamines [CAUTION // EVIDENCE_CONTEXT]
Additive sedation and impaired psychomotor performance are pharmacologically plausible; the cited GABA-A work is preclinical, not a quantified human interaction RCT.
PMID 34885687 PMID 33177986 - Caution Hormone treatment and hormonal contraception [CAUTION // EVIDENCE_CONTEXT]
8-PN has estrogen-receptor activity in preclinical models. Clinical interaction magnitude, including any effect on contraceptive effectiveness, is unestablished.
PMID 11134162 PMID 28964928 - Caution CYP-metabolized medicines [CAUTION // EVIDENCE_CONTEXT]
Xanthohumol/related compounds affect CYP1A1 and estrogen hydroxylation in vitro; clinical relevance is unknown.
PMID 27269377 PMID 17981005 - Caution Valerian, passionflower, lemon balm, chamomile or melatonin [CAUTION // EVIDENCE_CONTEXT]
The fixed valerian+hops combination is studied; additional sedative stacking may increase grogginess, without solid human interaction quantification.
PMID 16335333 PMID 17486686
Red flags: interactions and who should avoid it
Interactions
Alcohol, benzodiazepines, hypnotics, sedating antihistamines and other calming herbs may add to sedation; this is pharmacological reasoning rather than quantified human interaction trials. Potential overlap with hormone therapy/contraception and CYP-mediated metabolism is mainly theoretical or in vitro.
Avoid or ask a doctor first if
Avoid unsupervised use in pregnancy, breastfeeding and children because safety is inadequate. Estrogen-sensitive conditions, hormone therapy and psychiatric treatment warrant clinician review. Drowsiness can impair driving or machinery use. Stop/review problematic sedation or worsening mood; avoid combining with alcohol.
Sources (PubMed, 24)
- The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids.
PMID 11134162 · 2000 · catalogued study; design described in outcome context8-PN shows estrogen-receptor activity and mammary effects in cell/animal models. This is a safety-relevant pharmacological signal, not a beneficial wellness endpoint or proof of a human cancer outcome.
- Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense).
PMID 16076101 · 2005 · catalogued study; design described in outcome contextSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts.
PMID 16321485 · 2006 · randomized controlled trialSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial.
PMID 16335333 · 2005 · randomized controlled trialSmall/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
- The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes.
PMID 17088409 · 2006 · catalogued study; design described in outcome contextSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder.
PMID 17486686 · 2007 · randomized controlled trialSmall/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
- Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-inducing aid.
PMID 17704989 · 2007 · reviewSmall/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
- Antigenotoxic effect of Xanthohumol in rat liver slices.
PMID 17981005 · 2008 · catalogued study; design described in outcome contextXanthohumol/related compounds affect CYP1A1 and estrogen hydroxylation in vitro; clinical relevance is unknown.
- Treating primary insomnia - the efficacy of valerian and hops.
PMID 20628685 · 2010 · reviewSmall/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
- Hop extracts and hop substances in treatment of menopausal complaints.
PMID 23512496 · 2013 · reviewSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- Evaluation of estrogenic activity of licorice species in comparison with hops used in botanicals for menopausal symptoms.
PMID 23874474 · 2013 · catalogued study; design described in outcome context8-PN shows estrogen-receptor activity and mammary effects in cell/animal models. This is a safety-relevant pharmacological signal, not a beneficial wellness endpoint or proof of a human cancer outcome.
- Herbal preparations for the menopause: beyond isoflavones and black cohosh.
PMID 24314619 · 2014 · reviewSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- Biological and chemical standardization of a hop (Humulus lupulus) botanical dietary supplement.
PMID 24861737 · 2014 · catalogued study; design described in outcome contextThe dossier does not give an extract-mass range or actual xanthohumol/8-PN percentage. Do not treat an unspecified marker content as 100%.
- Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops.
PMID 25045111 · 2014 · catalogued study; design described in outcome contextThe dossier does not give an extract-mass range or actual xanthohumol/8-PN percentage. Do not treat an unspecified marker content as 100%.
- Hop (Humulus lupulus L.) Extract and 6-Prenylnaringenin Induce P450 1A1 Catalyzed Estrogen 2-Hydroxylation.
PMID 27269377 · 2016 · catalogued study; design described in outcome contextXanthohumol/related compounds affect CYP1A1 and estrogen hydroxylation in vitro; clinical relevance is unknown.
- Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action.
PMID 27617238 · 2016 · catalogued study; design described in outcome contextSmall standardized-extract RCTs suggest lower vasomotor discomfort over weeks. The source has a review protocol rather than a large completed meta-analysis; effect size and clinical generalizability remain uncertain.
- Effects of a hops (Humulus lupulus L.) dry extract supplement on self-reported depression, anxiety and stress levels in apparently healthy young adults: a randomized, placebo-controlled, double-blind, crossover pilot study.
PMID 28742505 · 2017 · randomized controlled trialOne double-blind crossover pilot in apparently healthy young adults found lower DASS-21 anxiety/depression/stress scores after four weeks; it is not replicated evidence for clinical anxiety/depression.
- Evaluation of estrogenic potency of a standardized hops extract on mammary gland biology and on MNU-induced mammary tumor growth in rats.
PMID 28964928 · 2017 · catalogued study; design described in outcome context8-PN shows estrogen-receptor activity and mammary effects in cell/animal models. This is a safety-relevant pharmacological signal, not a beneficial wellness endpoint or proof of a human cancer outcome.
- Sequential Elution of Essential Oil Constituents during Steam Distillation of Hops (Humulus lupulus L.) and Influence on Oil Yield and Antimicrobial Activity.
PMID 29877222 · 2018 · catalogued study; design described in outcome contextNo extracted clinical dose threshold or universal active percentage; traditional use is not a standardized trial.
- SAR Study on Estrogen Receptor α/β Activity of (Iso)flavonoids: Importance of Prenylation, C-Ring (Un)Saturation, and Hydroxyl Substituents.
PMID 32945668 · 2020 · catalogued study; design described in outcome context8-PN shows estrogen-receptor activity and mammary effects in cell/animal models. This is a safety-relevant pharmacological signal, not a beneficial wellness endpoint or proof of a human cancer outcome.
- Humulone Modulation of GABAA Receptors and Its Role in Hops Sleep-Promoting Activity.
PMID 33177986 · 2020 · catalogued study; design described in outcome contextAdditive sedation and impaired psychomotor performance are pharmacologically plausible; the cited GABA-A work is preclinical, not a quantified human interaction RCT.
- Effect of non-alcoholic beer containing matured hop bitter acids on mood states in healthy adults: A single-arm pilot study.
PMID 34741379 · 2022 · catalogued study; design described in outcome contextNo reliable supplement dose or universal bitter-acid exposure follows from beverage volume.
- GABAA Receptor-Mediated Sleep-Promoting Effect of Saaz-Saphir Hops Mixture Containing Xanthohumol and Humulone.
PMID 34885687 · 2021 · catalogued study; design described in outcome contextAdditive sedation and impaired psychomotor performance are pharmacologically plausible; the cited GABA-A work is preclinical, not a quantified human interaction RCT.
- Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial.
PMID 40462685 · 2025 · randomized controlled trialSmall/medium adult RCTs using fixed valerian+hops products found some subjective sleep/latency benefits. The Morin comparison did not establish clear placebo superiority on objective sleep measures; isolated hops efficacy remains unmeasured.
Community comments
No approved comments yet. Comments are held for moderation.